Skip to main content

Table 2 Hematological and metabolic parameters for the overall CGL cohort

From: Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa

 

Overall CGL cohort

Parameter

n(available)

Mean (± SD)

Median (range)

Hemoglobin (g/dL)

36

12.3 (± 2.0)

12.2 (8.2–16.6)

Platelet count (109 platelets/L)

36

361 (± 155)

330 (79–739)

Serum calcium (mmol/L)

29

2.4 (± 0.4)

2.4 (0.6–2.8)

Serum creatinine (µmol/L)

32

33 (± 17)

30 (12–80)

White blood cell count (109 cells/L)

36

9.2 (± 4.0)

8.6 (4.1–19.7)

ALT (IU/L)

35

66 (± 56)

46 (14–232)

AST (IU/L)

34

53 (± 32)

46 (15–187)

Creatine kinase (IU/L)

20

981 (± 1514)

150 (16–6000)

Fasting insulin (pmol/L)

17

384 (± 511)

79 (13–1611)

FPG (mmol/L)

23

8.9 (± 5.5)

5.4 (4.0–19.3)

GGT (IU/L)

16

66 (± 44)

49 (13–175)

HbA1c (%)

28

7.3 (± 3.1)

5.7 (4.5–14.3)

Total cholesterol (mmol/L)

29

4.9 (± 2.1)

4.3 (2.1–13.2)

Triglycerides (mmol/L)

33

6.1 (± 7.3)

2.9 (0.9–31.0)

  1. Data were obtained at the time of patient diagnosis and during leptin-replacement naïve follow-up visits as permitted by available medical records. Reference ranges: Fasting insulin, < 111 pmol/L (< 16 mUI/ml); FPG, 3.9–5.5 mmol/L (70–99 mg/dl); HbA1c, < 5.7%; Triglycerides, < 1.69 mmol/L (< 150 mg/dl); Total cholesterol, < 5.18 mmol/L (< 200 mg/dl) [11, 22, 31, 32]. ALT Alanine aminotransferase, AST Aspartate aminotransferase, CGL Congenital generalized lipodystrophy, FPG Fasting plasma glucose, GGT Gamma-glutamyl transferase, HbA1c Glycated hemoglobin, n Number of patients exhibiting the disease characteristic, n(available), Number of patients with available data, SD Standard deviation
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172